tbuckley/cabot-search huggingface dataset:
Tripartite motif‐containing protein 11 promotes hepatocellular carcinogenesis through ubiquitin‐proteasome–mediated degradation of pleckstrin homology domain leucine‐rich repeats protein phosphatase 1
Authors: Juan Yang, Jianming Ye, Tengfei Ma, Fangfang Tang, Li Huang, Zhen Liu, Song Tian, Xu Cheng, Li Zhang, Zhenli Guo, Fuping Tu, Miao He, Xueming Xu, Xiaojuan Lu, Yanyang Wu, Xiaoli Zeng, Jiahua Zou, Xiangcai Wang, Weijie Peng, Peng Zhang
Journal: Hepatology (2021)

HCC is one of the main types of primary liver cancer, with high morbidity and mortality and poor treatment effect. Tripartite motif-containing protein 11 (TRIM11) has been shown to promote tumor formation in lung cancer, breast cancer, gastric cancer, and so on. However, the specific function and mechanism of TRIM11 in HCC remain open for study.Through clinical analysis, we found that the expression of TRIM11 was up-regulated in HCC tissues and was associated with high tumor node metastasis (TNM) stages, advanced histological grade, and poor patient survival. Then, by gain- and loss-of-function investigations, we demonstrated that TRIM11 promoted cell proliferation, migration, and invasion in vitro and tumor growth in vivo. Mechanistically, RNA sequencing and mass spectrometry analysis showed that TRIM11 interacted with pleckstrin homology domain leucine-rich repeats protein phosphatase 1 (PHLPP1) and promoted K48-linked ubiquitination degradation of PHLPP1 and thus promoted activation of the protein kinase B (AKT) signaling pathway. Moreover, overexpression of PHLPP1 blocked the promotional effect of TRIM11 on HCC function.Our study confirmed that TRIM11 plays an oncogenic role in HCC through the PHLPP1/AKT signaling pathway, suggesting that targeting TRIM11 may be a promising target for the treatment of HCC.
Remodeling of the tumor microenvironment via disrupting Blimp1+ effector Treg activity augments response to anti-PD-1 blockade
Authors: Michael L. Dixon, Lin Luo, Sadashib Ghosh, Jeffrey M. Grimes, Jonathan D. Leavenworth, Jianmei W. Leavenworth
Journal: Molecular Cancer (2021)

Abstract Background Accumulation of Foxp3 + regulatory T (Treg) cells in the tumor often represents an important mechanism for cancer immune evasion and a critical barrier to anti-tumor immunity and immunotherapy. Many tumor-infiltrating Treg cells display an activated phenotype and express the transcription factor Blimp1. However, the specific impact of these Blimp1 + Treg cells and their follicular regulatory T (T FR ) cell subset on tumor and the underlying mechanisms of action are not yet well-explored. Methods Various transplantable tumor models were established in immunocompetent wild-type mice and mice with a Foxp3-specific ablation of Blimp1. Tumor specimens from patients with metastatic melanoma and TCGA datasets were analyzed to support the potential role of Treg and T FR cells in tumor immunity. In vitro culture assays and in vivo adoptive transfer assays were used to understand how Treg, T FR cells and antibody responses influence tumor control. RNA sequencing and NanoString analysis were performed to reveal the transcriptome of tumor-infiltrating Treg cells and tumor cells, respectively. Finally, the therapeutic effects of anti-PD-1 treatment combined with the disruption of Blimp1 + Treg activity were evaluated. Results Blimp1 + Treg and T FR cells were enriched in the tumors, and higher tumoral T FR signatures indicated increased risk of melanoma metastasis. Deletion of Blimp1 in Treg cells resulted in impaired suppressive activity and a reprogramming into effector T-cells, which were largely restricted to the tumor-infiltrating Treg population. This destabilization combined with increased anti-tumor effector cellular responses, follicular helper T-cell expansion, enhanced tumoral IgE deposition and activation of macrophages secondary to dysregulated T FR cells, remodeled the tumor microenvironment and delayed tumor growth. The increased tumor immunogenicity with MHC upregulation improved response to anti-PD-1 blockade. Mechanistically, Blimp1 enforced intratumoral Treg cells with a unique transcriptional program dependent on Eomesodermin (Eomes) expression; deletion of Eomes in Blimp1-deficient Treg cells restored tumor growth and attenuated anti-tumor immunity. Conclusions These findings revealed Blimp1 as a new critical regulator of tumor-infiltrating Treg cells and a potential target for modulating Treg activity to treat cancer. Our study has also revealed two FCERIA -containing immune signatures as promising diagnostic or prognostic markers for melanoma patients.
First-Mind: Primary Analysis from a Phase Ib, Open-Label, Randomized Study to Assess Safety of Tafasitamab or Tafasitamab + Lenalidomide in Addition to R-CHOP in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma
Authors: David Belada, Katerina Kopeckova, Juan Miguel Bergua Burgues, Don Stevens, Marc André, Ernesto Pérez Persona, Petra Pichler, Philipp B. Staber, Marek Trneny, Bettina Brackertz, Neha Shah, Andrea Sporchia, John M. Burke, Grzegorz S. Nowakowski
Journal: Blood (2021)
HDACi Targets IKZF1 Deletion High-Risk Acute Lymphoblastic Leukemia By Inducing IKZF1 Expression and Rescuing IKZF1 Function in Vitro and In Vivo
Authors: Kangyu Huang, Bingqing Tang, Zihong Cai, Xianjun He, Qiuli Li, Nannan Liu, Dainan Lin, Xinhua Pan, Ce Shi, Zijie Long, Jinheng Wang, Yumin Hu, Peng Li, Qifa Liu, Hongsheng Zhou
Journal: Blood (2021)
<i>NOTCH1</i> Mutation in CLL Enhances Cell Cycle G1/S Transition through Specific Cyclin Overexpression: Preclinical Ground for CDK4/6 Targeted Inhibition
Authors: Salvador Carrillo-Tornel, Tzu Hua Chen-Liang, María Zurdo, Anna Puiggros, Andrea Gómez-Llonín, María-Dolores García-Malo, Ernesto J Cuenca, Francisco José Ortuño, Ana M Hurtado López, Blanca Espinet, Andres Jerez
Journal: Blood (2021)
A Phase II Study of Daratumumab in Patients with High-Risk MGUS and Low-Risk Smoldering Multiple Myeloma
Authors: Omar Nadeem, Robert A. Redd, Michael Z. Koontz, Jeffrey V. Matous, Andrew J. Yee, Jeffrey A. Zonder, Andrew Kin, Jacalyn Rosenblatt, Julia Prescott, Kelsey Tague, Veronica Romines, Meredith Bertoni, Amada Metivier, Rebekah Medina, Alexandra Savell, Houry Leblebjian, Alexandra Distaso, Clifton C Mo, Jacob P. Laubach, Adam S. Sperling, Paul G. Richardson, Irene M. Ghobrial
Journal: Blood (2021)
Therapy-Related Cytopenia of Undetermined Significance (t-CCUS) As a Precursor to Therapy-Related Myeloid Neoplasms (t-MN)
Authors: Mithun V. Shah, Abhishek A. Mangaonkar, Kebede H. Begna, Hassan B. Alkhateeb, Patricia Greipp, Dong Chen, David S. Viswanatha, Rong He, Michelle A Elliott, William J Hogan, Mark R. Litzow, Kristen McCullough, Ayalew Tefferi, Naseema Gangat, Mrinal M. Patnaik, Aref Al-Kali
Journal: Blood (2021)
A Phase I Trial of PI3Kαδ Inhibitor Copanlisib in Combination with Nivolumab in Patients with Richter's Transformation (RT) or Transformed Non-Hodgkin Lymphoma (tNHL)
Authors: Geoffrey Shouse, Tanya Siddiqi, Leslie L. Popplewell, Alexandra Muir, Ivana Melgar, Brandy Gonzales, Kirsten Orand, Sandrine Puverel, Lili Wang, Adam S Kittai, Lu Chen, Matthew S. Davids, Alexey V. Danilov
Journal: Blood (2021)
Post-Transplant Cyclophosphamide Is Associated with Improved Clinical Outcomes in HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation
Authors: Antonio M. Jimenez, Miguel-Angel Perales, Sean M Devlin, Lazaros J. Lekakis, Craig S. Sauter, Denise Pereira, Amer Beitinjaneh, Samantha Brown, Trent Wang, Doris M Ponce, Mark S. Goodman, Stephanie Chinapen, Krishna V. Komanduri, Brian C Shaffer
Journal: Blood (2021)
Investigating the Roles of Platelet PAR4 in Hemostasis, Thrombosis and Viral Infection Using a Newly Generated PAR4 Floxed Mouse
Authors: Robert H Lee, Tomohiro Kawano, Vanthana Bharathi, David Martinez, Dale O Cowley, Steven P Grover, Nigel Mackman, Wolfgang Bergmeier, Silvio Antoniak
Journal: Blood (2021)
Subclinical Atrial Fibrillation: A Silent Threat with Uncertain Implications
Authors: Anthony H. Kashou, Demilade A. Adedinsewo, Peter A. Noseworthy
Journal: Annual Review of Medicine (2021)

Atrial fibrillation (AF) is one of the most common cardiac arrhythmias. Implantable and wearable cardiac devices have enabled the detection of asymptomatic AF episodes-termed subclinical AF (SCAF). SCAF, the prevalence of which is likely significantly underestimated, is associated with increased cardiovascular and all-cause mortality and a significant stroke risk. Recent advances in machine learning, namely artificial intelligence-enabled ECG (AI-ECG), have enabled identification of patients at higher likelihood of SCAF. Leveraging the capabilities of AI-ECG algorithms to drive screening protocols could eventually allow for earlier detection and treatment and help reduce the burden associated with AF.
Clinical Outcomes and Treatment Strategies for Relapsed/Refractory Myeloma Patients after Relapse on BCMA-Targeted CAR T
Authors: Oliver Van Oekelen, Tarek H. Mouhieddine, Darren Pan, Megan Metzger, Sarita Agte, Adolfo Aleman, David T. Melnekoff, Guido Lancman, Alessandro Lagana, Shambavi Richard, Larysa Sanchez, Joshua Richter, Hearn Jay Cho, Ajai Chari, Sundar Jagannath, Samir Parekh
Journal: Blood (2021)
Dynamic Reprogramming and Evolution Associated with Sequential Resistance to Ibrutinib and CAR T Therapy in Mantle Cell Lymphoma
Authors: Fangfang Yan, Changying Jiang, Qingsong Cai, Preetesh Jain, Yijing Li, Yang Liu, Joseph McIntosh, Alexa A Jordan, Zhongming Zhao, Lukas Simon, Michael Wang
Journal: Blood (2021)
Abstract P296: Poor Functional Capacity is Associated With Peripheral Microvascular Dysfunction in Coronary Artery Disease
Authors: Jeong Hwan Kim, Ahmed Al-Badri, Muhammad Hammadah, Ibhar Al Mheid, Kobina Wilmot, Ronnie Ramadan, Bruno Lima, Ayman Alkhoder, Naser Abdelhadi, Malik Obideen, Irina Uphoff, Mohamad Mazen Ghafeer, Belal Kaseer, Fahad Choudary, Amit Shah, Paolo Raggi, Viola Vaccarino, Arshed Quyyumi
Journal: Circulation (2018)

Introduction: Reduced functional capacity, assessed by self-reported Duke Activity Status Index (DASI) is associated with adverse outcomes. Peripheral microvascular dysfunction, measured as reduced digital reactive hyperemia index (RHI) is also associated with adverse events. Whether microvascular dysfunction is related to functional capacity is unknown. Hypothesis: We hypothesized that peripheral microvascular dysfunction is associated with diminished functional capacity. Methods: In 531 patients with stable CAD (age 62±9, 75% male, 30% Black, EF 55±13%) enrolled in the Mental Ischemia Prognosis Study, self-reported functional capacity was assessed with the DASI questionnaire with a score of &gt;25 as the cutoff for normal. Pulsatile arterial tonometry (EndoPat, Itamar Inc.) was used to measure digital RHI during 5 minutes of upper arm occlusion with blood pressure cuff followed by reperfusion. Logistic regression was used to model reduced RHI (&lt;median) as a function of normal vs low DASI score (&gt;25 vs ≤ 25). Results: Median RHI was 2.01 [IQR 1.67, 2.49] while median DASI score was 45 [29,53], equivalent to 8.3 METs. Compared to those with normal DASI score (&gt;25; N=425), subjects with low DASI score (≤25; N=106) had lower RHI (1.88 [1.64, 2.24] vs 2.06 [1.69, 2.54], P=0.048), higher BMI (32±7 kg/m 2 vs 29±5 kg/m 2 , P&lt;0.001), were more likely to be female (48% vs 20%, P&lt;0.001) and Black (42% vs 28%, P=0.005), and more likely to have a history of hypertension (87% vs 75%, P=0.009), diabetes (39% vs 29%, P=0.046), and heart failure (34% vs. 20%, P=0.003). After adjusting for the aforementioned variables in addition to history of dyslipidemia, smoking and prior MI, those with a low DASI score had a significantly higher likelihood of a reduced RHI (&lt;median) (OR 1.72, 95% CI 1.08 - 2.74, P=0.023) Conclusion: Poor functional capacity is independently associated with microvascular dysfunction in patients with stable CAD, and illustrates a potential mechanism by which reduced functional capacity increases cardiovascular risk. Whether improvement in functional capacity by exercise/rehabilitation programs improves microvascular function requires further investigation.
ALL Maintenance Treatment for Early Loss of B-Cell Aplasia after Tisagenlecleucel Therapy
Authors: Maria Gabelli, Macarena Oporto Espuelas, Denise Bonney, Saskia Burridge, Susan Farish, Khushnuma Mullanfiroze, Arina Lazareva, Sujith Samarasinghe, Philip Ancliffe, Ajay Vora, Jack Bartram, Emma Hedges, Kirsty Ware, Lindsey Young, Chiara Cugno, Lenka Chenchara, Juliana Silva, Oana Mirci-Danicar, Lynne Riley, Vesna Pavasovic, Anupama Rao, Paul Veys, Giovanna Lucchini, Robert Chiesa, Kanchan Rao, Persis J Amrolia, Sara Ghorashian
Journal: Blood (2021)
Preterm infant meconium microbiota transplant induces growth failure, inflammatory activation, and metabolic disturbances in germ-free mice
Authors: Henni Hiltunen, Hila Hanani, Raakel Luoto, Sondra Turjeman, Oren Ziv, Erika Isolauri, Seppo Salminen, Omry Koren, Samuli Rautava
Journal: Cell Reports Medicine (2021)

Preterm birth may result in adverse health outcomes. Very preterm infants typically exhibit postnatal growth restriction, metabolic disturbances, and exaggerated inflammatory responses. We investigated the differences in the meconium microbiota composition between very preterm (<32 weeks), moderately preterm (32–37 weeks), and term (>37 weeks) human neonates by 16S rRNA gene sequencing. Human meconium microbiota transplants to germ-free mice were conducted to investigate whether the meconium microbiota is causally related to the preterm infant phenotype in an experimental model. Our results indicate that very preterm birth is associated with a distinct meconium microbiota composition. Fecal microbiota transplant of very preterm infant meconium results in impaired growth, altered intestinal immune function, and metabolic parameters as compared to term infant meconium transplants in germ-free mice. This finding suggests that measures aiming to minimize the long-term adverse consequences of very preterm birth should be commenced during pregnancy or directly after birth.
Apheresis Products from Patients with Multiple Myeloma Treated with G-CSF Are a Suitable Source of T Cells for the Production of BCMA-Targeting CAR-T Cells
Authors: Anthony M Battram, Aina Oliver-Caldés, Miquel Bosch i Crespo, María Suárez-Lledó, Miquel Lozano, Nuria Martínez-Cibrian, Joan Cid, David F. Moreno, Luis Gerardo Rodríguez-Lobato, Alvaro Urbano-Ispizua, Carlos Fernandez de Larrea
Journal: Blood (2021)
Exploring Genotype:Phenotype Correlations at Baseline and at One Year for ET and PV Patients in the Majic Study
Authors: Chandan Saha, Carolyn Mead-Harvey, Adam J. Mead, Rebecca H. Boucher, Sonia Fox, Isaak Ailts, Christina Yap, Aimee E Jackson, Joanne Ewing, Jason Coppell, Steve Knapper, Mark W. Drummond, Anna L Godfrey, Amylou C. Dueck, Ruben A. Mesa, Robyn Scherber, Mary Frances McMullin, Holly L. Geyer, Claire N. Harrison
Journal: Blood (2021)
Characterizing the inclusion of pregnant and breastfeeding people in infectious diseases randomized controlled trials: a targeted literature review
Authors: Sarah C.J. Jorgensen, Simona Miljanic, Najla Tabbara, Deborah Somanader, Christopher L.Y. Tse, Charmaine De Castro, Isabelle Malhamé, Stephen E. LapinskY, Lisa Burry
Journal: Clinical Microbiology and Infection (2021)
Endoscopic submucosal dissection in the stomach under equal multi-traction from four directions
Authors: Kinya Fujita
Journal: Endoscopy (2021)

Although endoscopic submucosal dissection (ESD) has become widespread because of its higher cure rate for nonmetastatic gastrointestinal tumors [1] [2] [3], it is technically challenging. Therefore, several traction techniques have been developed [4] [5]. We report a case in which multi-traction was useful for gastric ESD.
Changing Patterns of Symptomatic Myeloma after the Implementation of the 2014 IMWG Diagnostic Criteria and Reduced Early Mortality
Authors: Efstathios Kastritis, Maria Gavriatopoulou, Maria Roussou, Evangelos Eleutherakis-Papaiakovou, Magdalini Migkou, Nikolaos Kanellias, Despina Fotiou, Foteini Theodorakakou, Ioannis Ntanasis-Stathopoulos, Panagiotis Malandrakis, Vasiliki Spiliopoulou, Stavroula Giannouli, Evangelos Terpos, Meletios A. Dimopoulos
Journal: Blood (2021)
Abstract 9396: Evaluation of the ABC Pathway for Comprehensive Management of Atrial Fibrillation in 20,933 Patients from the ENGAGE AF-TIMI 48 Trial
Authors: Siddharth M Patel, Sabina A Murphy, Elliott M Antman, Eugene Braunwald, Gregory Y Lip, Robert P Giugliano, Christian T Ruff
Journal: Circulation (2021)

Introduction: Pts with atrial fibrillation (AF) are at high risk of morbidity and mortality beyond ischemic stroke. The ABC (Atrial Fibrillation Better Care) comprehensive care approach was devised to improve overall care and is endorsed by the 2020 ESC AF Guideline. The impact of the ABC pathway in a large, well-phenotyped population is unclear. Methods: ENGAGE AF-TIMI 48 was an RCT of edoxaban vs. warfarin in pts with AF and CHADS 2 score ≥2. In this exploratory analysis, pts were classified as treated according to the ABC pathway if they met all components depicted in Fig 1 . CV outcomes were compared between pts whose care was vs. was not concordant with the ABC pathway using a Cox proportional hazards model including CHA 2 DS 2 -VASc score. Randomized treatment interaction was assessed using interaction p-values. Results: Of 20,933 pts, 35% were treated concordant with the ABC pathway. These pts were younger (age &lt;75y: 61.9% vs. 56.5%), had less frequent prior CAD (23.3% vs. 38.8%), DM (30.3% vs. 39.4%), and stroke/TIA (18.6% vs. 33.7%). Treatment consistent with the ABC pathway was associated with lower rates of stroke/SEE (HR 0.58, 95% CI 0.50-0.67), major bleeding (HR 0.71, 95% CI 0.62-0.81), MACE (HR 0.57, 95% CI 0.52-0.62), and CV death (HR 0.57, 95% CI 0.50-0.64; p&lt;0.001 for each; Fig 2 ). Lower rates of CV events in patients treated according to the ABC pathway were generally consistent by randomized treatment. Conclusions: In this non-randomized analysis, comprehensive management of AF consistent with the ABC pathway as outlined by the 2020 ESC Guideline on AF is associated with lower adjusted rates of multiple CV outcomes including CV mortality.
A Phase 2 Study to Test the Feasibility, Safety and Efficacy of the Addition of Blinatumomab to the Interfant06 Backbone in Infants with Newly Diagnosed <i>KMT2A</i>-Rearranged Acute Lymphoblastic Leukemia. a Collaborative Study of the Interfant Network
Authors: Inge M. Van Der Sluis, Paola De Lorenzo, Rishi Sury Kotecha, Andishe Attarbaschi, Gabriele Escherich, Karsten Nysom, Jan Stary, Alina Ferster, Benoit Brethon, Phillip Ancliff, Andrea Biondi, Maria Grazia Valsecchi, Rob Pieters
Journal: Blood (2021)
COVID-19 in vaccinated adult patients with hematological malignancies: preliminary results from EPICOVIDEHA
Authors: Livio Pagano, Jon Salmanton-García, Francesco Marchesi, Alberto López-García, Sylvain Lamure, Federico Itri, Maria Gomes-Silva, Giulia Dragonetti, Iker Falces-Romero, Jaap van Doesum, Uluhan Sili, Jorge Labrador, Maria Calbacho, Yavuz M. Bilgin, Barbora Weinbergerová, Laura Serrano, José-María Ribera-Santa Susana, Sandra Malak, José Loureiro-Amigo, Andreas Glenthøj, Raúl Córdoba-Mascuñano, Raquel Nunes-Rodrigues, Tomás-José González-López, Linda Katharina Karlsson, María-Josefa Jiménez-Lorenzo, José-Ángel Hernández-Rivas, Ozren Jaksic, Zdeněk Ráčil, Alessandro Busca, Paolo Corradini, Martin Hoenigl, Nikolai Klimko, Philipp Koehler, Antonio Pagliuca, Francesco Passamonti, Oliver A. Cornely
Journal: Blood (2021)

In a Plenary Paper, Mittelman and colleagues assess the relative clinical efficacy of mRNA vaccination on COVID-19 disease incidence and outcomes in patients with hematologic malignancies compared with healthy matched controls. This population-based study from Israel links prior observations of poor serologic responses to vaccination to higher risk for breakthrough infection, hospitalization, and death in patients with blood cancer, especially those on active antineoplastic therapy. In an accompanying Letter to Blood, Pagano et al provide supportive data using a multination survey approach to capture outcomes for COVID-19 in vaccinated patients with hematologic neoplasms. They also emphasize the higher risk among patients with lymphoid malignancies. Together, these findings argue for both continued deployment of booster programs and ongoing public health guidance for this vulnerable group.
Role of oncogenic KRAS in the prognosis, diagnosis and treatment of colorectal cancer
Authors: Gongmin Zhu, Lijiao Pei, Hongwei Xia, Qiulin Tang, Feng Bi
Journal: Molecular Cancer (2021)

Abstract Colorectal cancer (CRC) is a heterogeneous disease at the cellular and molecular levels. Kirsten rat sarcoma ( KRAS ) is a commonly mutated oncogene in CRC, with mutations in approximately 40% of all CRC cases; its mutations result in constitutive activation of the KRAS protein, which acts as a molecular switch to persistently stimulate downstream signaling pathways, including cell proliferation and survival, thereby leading to tumorigenesis. Patients whose CRC harbors KRAS mutations have a dismal prognosis. Currently, KRAS mutation testing is a routine clinical practice before treating metastatic cases, and the approaches developed to detect KRAS mutations have exhibited favorable sensitivity and accuracy. Due to the presence of KRAS mutations, this group of CRC patients requires more precise therapies. However, KRAS was historically thought to be an undruggable target until the development of KRAS G12C allele-specific inhibitors. These promising inhibitors may provide novel strategies to treat KRAS -mutant CRC. Here, we provide an overview of the role of KRAS in the prognosis, diagnosis and treatment of CRC.
The Glucocorticoid Receptor-Dependent Stress Response in Human Erythropoiesis Is BCL11A-Dependent
Authors: Lilian Varricchio, Eliza Geer, Fabrizio Martelli, Maria Mazzarini, Alister Funnell, James J Bieker, Thalia Papayannopoulou, Anna Rita Migliaccio
Journal: Blood (2021)
Stool microbiota are superior to saliva in distinguishing cirrhosis and hepatic encephalopathy using machine learning
Authors: Krishnakant Saboo, Nikita V. Petrakov, Amirhossein Shamsaddini, Andrew Fagan, Edith A. Gavis, Masoumeh Sikaroodi, Sara McGeorge, Patrick M. Gillevet, Ravishankar K. Iyer, Jasmohan S. Bajaj
Journal: Journal of Hepatology (2021)
Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia with Hyperdiploid Complex Karyotype: A Study from the Acute Leukemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT)
Authors: Xavier Poiré, Myriam Labopin, Emmanuelle Polge, Arnold Ganser, Gerard Socie, Tobias Gedde-Dahl, Edouard Forcade, Jürgen Finke, Yves Chalandon, Claude-Eric Bulabois, Ibrahim Yakoub-Agha, Mahmoud Aljurf, Nicolaus Kröger, Igor Wolfgang Blau, Arnon Nagler, Jordi Esteve, Mohamad Mohty
Journal: Blood (2021)
Analysis of the Proteomes of Primary, De Novo Acute Myeloid Leukemia Cells from Adults
Authors: Michael H Kramer, Qiang Zhang, Robert W. Sprung, Petra Erdmann-Gilmore, Daniel R George, Nichole M Helton, Sharon E Heath, Jacqueline E. Payton, Peter Westervelt, Christopher A Miller, Matthew J. Walter, Daniel C. Link, John F. DiPersio, R Reid Townsend, Timothy J Ley
Journal: Blood (2021)
<i>In silico</i> Prediction Followed By I <i>n Vitro</i> validation Identifies a Survivin Inhibitor and an MCL-1 Inhibitor As a Potent Secondary Drug Against Refractory or Relapsed Mantle Cell Lymphoma
Authors: Sayak Chakravarti, Ujjal Kumar Mukherjee, Suman Mazumder, Timothy Moore, Amit Kumar Mitra
Journal: Blood (2021)
Spliceosome Mutant Myeloid Malignancies Are Preferentially Sensitive to PARP Inhibition
Authors: Dang Hai Nguyen, Zhiyan Silvia Liu, Sayantani Sinha, Maxwell Bannister, Erica Arriaga-Gomez, Axia Song, Dawei Zong, Victor Corral, Cassandra Leibson, Sumit Rai, Timothy A. Graubert, Stanley C Lee
Journal: Blood (2021)